Slide 1: Merck Oncology Overview ESMO 2020
Merck Oncology Overview ESMO 2020
Slide 2: Forward-looking statement
Forward-looking statement This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current bel
Slide 3: Executing on a broad oncology strategy to improve outcomes for cancer patients
Extensive new data at ESMO further highlights how we are executing on a broad oncology strategy to improve outcomes for cancer patients globally Further establish Broadly explore Advance pipeline Identify patients KEYTRUDA as combinations to and pursue strategic most likely to foundational treatment
Slide 4: Comprehensive KEYTRUDA development program
Comprehensive KEYTRUDA development program >900 Combination trials >110 Trials in >1,300 adjuvant / neoadjuvant Ongoing and earlier lines clinical trials >90 Registrational trials under way 4
Slide 5: Shaping the future with robust portfolio and pipeline
We have an opportunity to shape the future by leveraging our robust portfolio and pipeline… Expanding the IO-IO strategy by Pembro Pembro Pembro leveraging internal assets and expanding + + + combination possibilities with targeted ILT4 CTLA-4 TIGIT BTKi HIF-2α small molecules Ladiratuzumab Diversif
Slide 6: ESMO 2020: New, long-term and early data from broad portfolio
ESMO 2020: New, long-term and early data from broad portfolio Presenting New Data … … Demonstrating New Phase 3 data for KEYTRUDA in Long-Term Benefits ... … And Progressing Novel 1L Esophageal (KN-590) Mechanisms New combination data with KEYTRUDA + LENVIMA in melanoma Long-term survival data for a
Slide 7: KEYNOTE-590: KEYTRUDA in 1L esophageal cancer with chemotherapy
KEYNOTE-590: new KEYTRUDA data in 1L esophageal cancer in combination with chemotherapy demonstrated superior overall survival and progression-free survival compared to chemotherapy KEYTRUDA plus chemotherapy reduced risk of death by 27% compared to chemotherapy as 1L treatment for patients with met
Slide 8: LEAP-004: KEYTRUDA + LENVIMA in melanoma
LEAP-004: KEYTRUDA + LENVIMA in stage III melanoma introduces potential new treatment for PD-1/L1 refractory patients LENVIMA in combination with KEYTRUDA showed antitumor activity in patients with advanced melanoma with confirmed progression on a PD-1/L1 inhibitor • 21.4% BICR-confirmed ORR by RECI
Slide 9: Long-term follow-up confirms durable OS benefits of KEYTRUDA
Long-term follow-up data confirm durable OS benefits of KEYTRUDA monotherapy in combination with chemo or as adjuvant following surgery +XX% YOY NSCLC Head and Neck Melanoma The survival rate after five years from patients Long-term follow-up from KN-048 showed In a 3-yr follow-up on KEYNOTE-054, in
Slide 10: Long-term follow-up data for LYNPARZA demonstrates OS benefit
Long-term follow-up data for LYNPARZA demonstrates OS benefit in BRCA1/2- or ATM-mutated mCRPC and PFS in BRCAm advanced ovarian cancer 100 Olaparib Control 90 (N=162) (N=83) Events, n (%) 91 (56) 57 (69) 80 Median OS 19.1 months 14.7 months 70 0.69 Overall survival (%) HR (95% CI) 60 (0.50‒0.97); P
Slide 11: Vibostolimab (TIGIT): first-time data in advanced NSCLC
Vibostolimab (TIGIT): first-time data from cohort expansion in patients with advanced NSCLC naïve to anti-PD-1/L1 therapy show compelling response rates Vibostolimab is a monoclonal antibody that inhibits the T-Cell checkpoint inhibitor TIGIT Vibostolimab in combination with KEYTRUDA showed compelli
Slide 12: MK-4830 (ILT4): first-time Phase 1 efficacy data
MK-4830 (ILT4): first-time initial efficacy data from Phase 1 dose escalation study shows potential for asset in solid tumors ILT4 preliminary efficacy data showed an ORR of 24% (8/34) in patients who received MK-4830 in combination with KEYTRUDA Among 11 patients who progressed on prior PD-1 therap
Slide 13: MK-6482 (HIF-2α): updated data in VHL-associated disease
MK-6482 (HIF-2α): updated data on VHL-associated cRCC and non-RCC disease shows promising overall response rates Areas of the Body Affected by von Hippel-Lindau Disease Promising clinical activity was observed with MK- 6482 in treatment-naive patients with VHL- associated RCC • Confirmed ORR, 36.1 %
Slide 14: Collaborations, licensing agreements, and acquisitions
We have pursued collaborations, licensing agreements, and acquisitions that will increase our ability to provide benefit to cancer patients Company Development Program Development Stage * Strategic collaborations will enable us to further diversify Merck’s broad ladiratuzumab vedotin (LV) Phase 2 on
Slide 15: Q&A
Q&A To ask a question on the operator-assisted audio line, press *1. Note: be sure to mute your computer speakers if you are listening to the audio webcast. 15
Slide 16: Appendix
Appendix & MercK ©
Slide 17: KEYTRUDA has demonstrated activity in more than 30 types of cancer
KEYTRUDA has now demonstrated activity in more than 30 different types of cancer defined by site of origin, histology, or genetic markers Melanoma1 NSCLC2 H&N3 Urothelial4 TNBC5 Gastric6 cHL7 NHL PMBCL8 Mesothelioma9 100 100 100 100 100 100 100 100 100 0 0 0 0 0 0 0 0 0 -100 -100 -100 -100 -100 -100
Slide 18: KEYTRUDA improved overall survival in Phase 3 studies across malignancies
KEYTRUDA monotherapy and in combination improved overall survival in Phase 3 studies across a broad range of malignancies KEYNOTE-361 KEYNOTE-006 KEYNOTE-040 KEYNOTE-181 KEYNOTE-240 KEYNOTE-119 KEYNOTE-045 Pembro vs Chemo Pembro vs Ipi Pembro vs SOC Pembro vs Chemo Pembro vs Placebo Pembro vs Chemo
Slide 19: Broad adjuvant program with 20 registrational studies ongoing
KEYTRUDA is being explored in a broad adjuvant program with 20 registrational studies ongoing 2018 2019 2020 2021 2022 2023 2024 2025 2026+ Adjuvant TNBC cSCC Locally HNSCC Adjuvant Adjuvant Gastric & NSCLC Neo/adjuvant TNBC Adjuvant Melanoma Neoadjuvant / Advanced (KEYNOTE-412) Melanoma Esophageal
Slide 20: KEYTRUDA+LYNPARZA combination (KEYLYNK) and LYNPARZA programs
Extensive KEYTRUDA+LYNPARZA combination (KEYLYNK) and LYNPARZA monotherapy programs Tumor • mCRPC, All Comers (KEYLYNK-010) Tumor Agnostic • 1L, nonBRCA, KEYTRUDA combo (KEYLYNK-001) agnostic • mCRPC, HRRm (PROfound) - Approved • 1L Maintenance BRCA+ (SOLO-1) - Approved • mCRPC, All Comers Combo + A
Slide 21: KEYTRUDA+LENVIMA combination (LEAP) and LENVIMA programs
Extensive KEYTRUDA+LENVIMA combination (LEAP) and LENVIMA monotherapy programs • 1L PD-L1+ HNSCC (LEAP- 010) • 1L NSQ Combo with KEYTRUDA and Chemo (LEAP-006) Basket trial • 1L PD-L1+ NSCLC (LEAP-007) Head & neck • 2L NSQ (LEAP-008) cancer Urothelial • TNBC • 1L EC (LEAP-001) cancer • Gastric • 2L E
Slide 22: Early oncology pipeline of investigational immuno-therapeutic candidates
Early oncology pipeline* includes more than 20 investigational immuno-therapeutic candidates – including novel combinations with KEYTRUDA Pre-Clinical Phase 1 Phase 1/2 Phase 2 Molecules designed to RIG-I receptor CD-27 agonist stimulate immune system Immune functions, such as enhancing (MK-4621) (M